Skip to main content
. Author manuscript; available in PMC: 2014 Aug 25.
Published in final edited form as: Expert Rev Proteomics. 2013 Feb;10(1):65–75. doi: 10.1586/epr.12.67

Figure 2. Screening cross-reactivity.

Figure 2

Figure 2

(A) Binding signals of anti-VEGF, anti-GCSF, and anti-CRP antibodies after the antibodies are sequentially added. No cross-reactivity is observed. (B) Binding signals of anti-B2M, anti-EGFR, and anti-EpCAM antibodies after the antibodies are sequentially introduced. Cross-reactivity between anti-EGFR and EpCAM antigen is observed. ∆R/R: Changes in resistance over nominal (quiescent) resistance; B2M: β2-microglobulin; BSA: Bovine serum albumin; CRP: C-reactive protein; EGFR: EGF receptor; EpCAM: Epithelial cell adhesion molecule.

HHS Vulnerability Disclosure